Somatostatin receptor PET/MR imaging of inflammation in patients with large vessel vasculitis and atherosclerosis.
Author(s)
Type
Journal Article
Abstract
BACKGROUND: Assessing inflammatory disease activity in large vessel vasculitis (LVV) can be challenging by conventional measures. OBJECTIVES: We aimed to investigate somatostatin receptor 2 (SST2) as a novel inflammation-specific molecular imaging target in LVV. METHODS: In a prospective, observational cohort study, in vivo arterial SST2 expression was assessed by positron emission tomography/magnetic resonance imaging (PET/MRI) using 68Ga-DOTATATE and 18F-FET-βAG-TOCA. Ex vivo mapping of the imaging target was performed using immunofluorescence microscopy; imaging mass cytometry; and bulk, single-cell, and single-nucleus RNA sequencing. RESULTS: Sixty-one participants (LVV: n = 27; recent atherosclerotic myocardial infarction of ≤2 weeks: n = 25; control subjects with an oncologic indication for imaging: n = 9) were included. Index vessel SST2 maximum tissue-to-blood ratio was 61.8% (P < 0.0001) higher in active/grumbling LVV than inactive LVV and 34.6% (P = 0.0002) higher than myocardial infarction, with good diagnostic accuracy (area under the curve: ≥0.86; P < 0.001 for both). Arterial SST2 signal was not elevated in any of the control subjects. SST2 PET/MRI was generally consistent with 18F-fluorodeoxyglucose PET/computed tomography imaging in LVV patients with contemporaneous clinical scans but with very low background signal in the brain and heart, allowing for unimpeded assessment of nearby coronary, myocardial, and intracranial artery involvement. Clinically effective treatment for LVV was associated with a 0.49 ± 0.24 (standard error of the mean [SEM]) (P = 0.04; 22.3%) reduction in the SST2 maximum tissue-to-blood ratio after 9.3 ± 3.2 months. SST2 expression was localized to macrophages, pericytes, and perivascular adipocytes in vasculitis specimens, with specific receptor binding confirmed by autoradiography. SSTR2-expressing macrophages coexpressed proinflammatory markers. CONCLUSIONS: SST2 PET/MRI holds major promise for diagnosis and therapeutic monitoring in LVV. (PET Imaging of Giant Cell and Takayasu Arteritis [PITA], NCT04071691; Residual Inflammation and Plaque Progression Long-Term Evaluation [RIPPLE], NCT04073810).
Date Issued
2023-01-31
Date Acceptance
2022-10-24
Citation
Journal of the American College of Cardiology, 2023, 81 (4), pp.336-354
ISSN
0735-1097
Publisher
Elsevier
Start Page
336
End Page
354
Journal / Book Title
Journal of the American College of Cardiology
Volume
81
Issue
4
Copyright Statement
© 2023 THE AUTHORS. PUBLISHED BY ELSEVIER ON BEHALF OF THE AMERICAN
COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER
THE CC BY LICENSE ( http://creativecommons.org/licenses/by/4.0/ ) .
COLLEGE OF CARDIOLOGY FOUNDATION. THIS IS AN OPEN ACCESS ARTICLE UNDER
THE CC BY LICENSE ( http://creativecommons.org/licenses/by/4.0/ ) .
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/36697134
PII: S0735-1097(22)07441-1
Subjects
Takayasu arteritis
atherosclerosis
giant cell arteritis
inflammation
molecular imaging
somatostatin receptor
Humans
Receptors, Somatostatin
Prospective Studies
Fluorodeoxyglucose F18
Inflammation
Positron-Emission Tomography
Magnetic Resonance Imaging
Takayasu Arteritis
Coronary Vessels
Atherosclerosis
Myocardial Infarction
Giant Cell Arteritis
Radiopharmaceuticals
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2023-01-23